Clinical Ink, a global clinical technology company, offers data certainty from source to submission. Our Lunexis eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules — a suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source — naturally enhance your clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources as your trials progress. Visit clinicalink.com.


Clinical Ink

110 Gibraltar Road, Suite 150

Horsham, PA 19044



  • A pharmaceutical company is conducting a large clinical trial to evaluate its Alzheimer’s disease therapy in older adults. Because the sponsor wanted to conduct assessments remotely, it needed a data capture platform that would facilitate complex central nervous system (CNS) eCOA via telehealth.

  • Download this white paper to find out how the Lunexis eSource Ecosystem positively impacted the study workloads, efficiency, and data quality of more than 500 site users.

  • A large pharmaceutical company aimed to conduct a Phase IV post-marketing study with a streamlined randomization process using the in-house clinics of a US drugstore chain. Read about the solution and results in the available case study.

  • A U.K.-based life sciences company needed a data capture platform that could capture 10 early-stage studies running simultaneously. Lunexis supported all those studies with remote development and deployment. Study teams moved from study to study and room to room while capturing data on a single platform. Download our case study for the details.

  • Usability testing is a critical step when you want to create a positive patient experience. For a recent study, we examined how eCOA fared among teens with Type 1 diabetes and their parents. Read the poster to find out how electronic data collection performed compared to in-person.

  • eCOA translations don’t have to be overly complicated or time-consuming. When vendors work together, they create efficiencies that benefit both the sponsor and the patients. This article explains how translation specialist RWS and Clinical Ink collaborated to create a new tool that streamlines review and approval of translated eCOA screens.

  • Reach database lock in less than one month instead of a year. That’s what one large pharmaceutical company achieved by providing real-time remote access to validated clinical data. How did they do it? Read the case study to find out.

  • Direct Data Capture (DDC) and Electronic Data Capture (EDC). They sound the same. But when you dig a little deeper, there are fundamental, crucial distinctions that make a significant difference in clinical research workflows, data quality, and timelines. Here, we briefly cover the differences and answer some of the biggest questions we get from clients surrounding DDC.

  • The idea of BYOD for use in clinical trials during any phase has historically been conceptualized as a futuristic alternative, rather than what it actually is — a viable option for many clinical trials. While there has typically been hesitance among sponsors and CROs to choose a BYOD model for their study, there is an increasing number of trials that have successfully deployed this model with great results. Read more about the Advantages and Misconceptions of BYOD and what you should consider if you are deciding whether BYOD is an option for your study.

  • As the pioneers in eSource, we know our solutions must fit patients’ and sites’ day-to-day realities. Lunexis ePRO+ enhancements provide the adaptability to support clinical trial patients and their physicians in today’s unpredictable world.

  • In order to ensure a fluid experience for a patient, usability testing is a critical data point to consider. Addressing both a patient’s needs and access to a digital platform is key to data collection. TransPerfect, along with our partners from Parexel, Clinical Ink, and Health Psychology Research, recently published a poster at the Virtual ISPOR Europe 2020 conference that reviews the impact of moving from in-person to electronic data collection.

  • For infectious disease studies of any kind, the ability to accelerate trial timelines, while also providing high-quality data and reducing barriers to patient participation, is highly prized. eSource DDC, ePRO, and eCOA all help sponsors generate the data they need in real time — with less face-to-face interaction.

  • If you want to meet patients where they are and make data available to CROs and sponsors in real time, eliminating the majority of SDV is key. With evolving infectious disease situations, near-immediate access enables teams to respond to individual or epidemiologic developments right away. Learn about a leading pharma company’s Phase III trial for a SARS-CoV-2 prophylactic therapy in 1,000+ patients at 82 sites.

  • Decentralized trials; televisits; bring your own device (BYOD) — at the end of the day, it’s all about enabling a complete, flexible, adaptable journey for sponsors, sites, and especially, patients. What data collection methodology you choose has crucial implications for clinical research workflows, data quality, visibility, and timelines. How do you rapidly deploy an integrated, convenient data capture solution that provides anytime, anywhere access to clean study data, fast? Read the blog to find out.

  • While decentralized trial models and ePRO are both accepted in the industry, some sponsors have hesitated on BYOD due to questions over data quality, integrity, and variability; regulatory acceptance; and logistical issues. This article dispels common myths about BYOD.

  • This paper describes the complexity of GI trials in detail and shows a solution that is designed to overcome their significant, but typical, challenges.

  • In oncology clinical research, patient reported outcomes (PRO) have historically been collected on paper. This white paper describes a unique, agile ePRO deployment methodology used by a global clinical trial technology company, discusses the benefits of using ePRO in oncology trials, and explains why this agile process is beneficial for oncology trials.

  • You need streamlined, intuitive ePRO and ClinRO technology that expedites oncology workflows, lessens the burden on patients, and saves caregivers time. This blog explains how Clinical Ink’s robust, configurable platform connects sponsors, CROs, sites, and patients, fostering better cancer research and a higher standard of care.

  • The needs of the clinical trial protocol — not the limitations of technology — should determine how a study is deployed. That said, until now, data collection technology has constrained data collection and review. To achieve a flexible, patient-driven design, we needed to make our system even more powerful and adaptable.

  • CNS and pain trials are demanding from a data capture standpoint: Complicated eligibility criteria, extensive monitoring requirements, comprehensive data collection, and substantial demands on patients all must be overcome. After consulting with key opinion leaders from CROs and pharma we learned the solution was a product with a well-thought-out functionality specific to the therapeutic area coupled with highly consultative, experience-based guidance that ensures clients receive a complete data collection solution that fulfills their exact needs.